MARKET

EVFM

EVFM

Evofem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.565
+0.075
+3.01%
Opening 14:43 10/22 EDT
OPEN
2.510
PREV CLOSE
2.490
HIGH
2.570
LOW
2.480
VOLUME
420.44K
TURNOVER
--
52 WEEK HIGH
7.50
52 WEEK LOW
1.910
MARKET CAP
208.48M
P/E (TTM)
-1.3793
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Evofem's Major Sell-Off Undervalues The Company's Long-Term Potential
Evofem vaginal pH modulation technology is a differentiated product being used to target unmet needs in women’s health.Currently-approved Phexxi will likely have peak sales higher than Evofem’s current market cap.Evofem is likely a big long-term bargain after its recent large sell-off.
Seekingalpha · 1d ago
Evofem commences late-stage study of EVO100 for the prevention of STDs in women
Enrollment is underway in a Phase 3 clinical trial, EVOGUARD, evaluating Evofem Biosciences' ([[EVFM]] +0.4%) EVO100 vaginal gel for the prevention of urogenital chlamydia ((CT)) and gonorrhea ((GC)), sexually transmitted
Seekingalpha · 2d ago
Evofem Biosciences Announces First Patient Enrolled in Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and Gonorrhea
Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced enrollment of the first patient in its pivotal Phase 3 clinical trial evaluating the safety and efficacy of EVO100 for the prevention of urogenital chlamydia and gonorrhea in women.
PR Newswire · 2d ago
SNBR, GRFS among premarket gainers
SPI Energy (SPI) +56% on entering agreement with Shaanxi Tongjia Automobile.Anavex Life Sciences (AVXL) +36% after completing mid-stage study of lead drug in rare brain development disorder.Organogenesis Holdings (ORGO) +27% on Q3 preliminary results.Huttig Building Products
Seekingalpha · 10/15 12:24
Evofem Biosciences trades high on $25M strategic investment
Evofem Biosciences (EVFM) +2.9% PM, sold $25M of unsecured convertible promissory notes to funds affiliated with Adjuvant Capital; notes are convertible into Evofem shares at a conversion price of $3.65/share.Proceeds from notes
Seekingalpha · 10/15 12:10
Unusual Options Activity Insight: Evofem Biosciences
On Thursday, shares of Evofem Biosciences (NASDAQ: EVFM) saw unusual options activity. After the option alert, the stock price moved up to $2.88. * Sentiment: BULLISH * Option Type: SWEEP * Trade Type: CALL * Expiration Date: 2021-01-15 * Strike Price: $5.00 * Volume: 485 * Open Interest: 3904Three
Benzinga · 10/08 14:15
Evofem Biosciences Announces Presentations on Phexxi and EVO100 at Key Medical Society Meetings
Evofem Biosciences, Inc., (NASDAQ: EVFM) announced today that new clinical trial data on Phexxi™ (lactic acid, citric acid and potassium bitartrate) and EVO100 are being discussed in oral and poster presentations at major medical society meetings this month.
PR Newswire · 10/07 13:00
Evofem Biosciences initiated at buy with $5 price target at Stifel
EVFM | Complete Evofem Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
marketwatch.com · 10/02 11:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EVFM. Analyze the recent business situations of Evofem through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EVFM stock price target is 8.60 with a high estimate of 15.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 184
Institutional Holdings: 63.50M
% Owned: 78.13%
Shares Outstanding: 81.28M
TypeInstitutionsShares
Increased
41
10.06M
New
85
3.13M
Decreased
40
10.13M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.03%
Pharmaceuticals & Medical Research
+0.32%
Key Executives
Chairman/Director
Thomas Lynch
President/Chief Executive Officer/Director
Saundra Pelletier
Chief Financial Officer
Justin File
Executive Vice President/General Counsel/Secretary
Alexander Fitzpatrick
Other
Russell Barrans
Other
Russ Barrans
Other
Kelly Culwell
Independent Director
Gillian Greer
Independent Director
William Hall
Independent Director
Kim Kamdar
Independent Director
Tony O'Brien
Independent Director
Lisa Rarick
Independent Director
Colin Rutherford
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About EVFM
Evofem Biosciences Inc, formerly Neothetics, Inc., is a clinical-stage specialty biopharmaceutical company. The Company develops products to address unmet needs in women's sexual and reproductive health. The Company’s product Amphora, is a Multipurpose Vaginal pH Regulator (MVP-R) designed to regulate vaginal pH to within the normal range of 3.5 to 4.5 even in the presence of semen. This maintains an acidic environment which is inhospitable to sperm as well as certain viral and bacterial pathogens associated with sexually transmitted infections. Amphora is used to prevent urogenital chlamydia and gonorrhea in women. The Company is in the second Phase III clinical trial of Amphora for prevention of pregnancy (AMP002). The Company is currently designing a Phase IIb trial for its second product candidate, a MVP-R to reduce the recurrence of bacterial vaginosis.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Evofem Biosciences Inc stock information, including NASDAQ:EVFM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVFM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVFM stock methods without spending real money on the virtual paper trading platform.